D. Boral Capital Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $34.00 price objective on the stock.

A number of other research firms have also recently commented on NRXP. Ascendiant Capital Markets reaffirmed a “buy” rating and set a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. Finally, HC Wainwright increased their price target on NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

NRx Pharmaceuticals Stock Up 0.3%

NRXP traded up $0.01 during trading on Monday, reaching $1.71. The company had a trading volume of 546,183 shares, compared to its average volume of 1,112,837. The business has a 50 day simple moving average of $2.08 and a 200-day simple moving average of $2.49. The stock has a market cap of $54.34 million, a P/E ratio of -0.73 and a beta of 1.97. NRx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $3.84.

Institutional Trading of NRx Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Anson Funds Management LP grew its position in shares of NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after buying an additional 1,018,853 shares during the last quarter. Vanguard Group Inc. increased its position in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares in the last quarter. Commonwealth Equity Services LLC purchased a new stake in NRx Pharmaceuticals in the fourth quarter valued at about $994,000. AdvisorShares Investments LLC raised its stake in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after acquiring an additional 33,004 shares in the last quarter. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.